COMPOSITIONS AND METHODS RELATED TO TAUOPATHY

摘要

Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2.

主权项

1. An isolated polypeptide comprising a core pentapeptide sequence having the general formula aa5-aa4-aa3-aa2-aa1, with the proviso that the isolated polypeptide is not a native full-length tau protein, wherein aa5 is tyrosine or phenylalanine, wherein aa4 is lysine, aspartic acid, serine, or cysteine, wherein aa3 is proline or valine, wherein aa2 is valine, phenylalanine, alanine, or tyrosine, and wherein aa1 is aspartic acid.